psilocybin – Discover Pharma

Welcome to Discover Pharma! Today is : August 25, 2026

psilocybin

Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Compass Pathways study explores monitoring and support in COMP360 PTSD trial
Compass Pathways has published a post hoc analysis of its [...]

July 17, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression
Compass Pathways has reported positive six-month results from its second [...]

July 8, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Incannex links PSX-001 psilocybin programme to White House push on psychedelic mental health treatments
Incannex Healthcare has said its PSX-001 oral synthetic psilocybin programme [...]

May 14, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
Compass Pathways reports positive second Phase 3 trial for COMP360 in treatment-resistant depression
Compass Pathways has reported that its second pivotal Phase 3 [...]

May 5, 2026
Biotech & Pharma Business,Therapeutic Areas
Biotech and psychedelics converge: Psylink CEO Laura Korsakova on reshaping mental health at Baltic Life Sciences
Speaking at Baltic Life Sciences, Laura Korsakova, co-founder and CEO [...]

May 5, 2026
Clinical & Regulatory,Drug Discovery & Development
High hopes: Ajna turns psychedelics and cannabis into prescription science
May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK